ID
45757
Beskrivning
Principal Investigator: Daphne W. Bell, PhD, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA MeSH: Endometrial Neoplasms,Carcinosarcoma https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001152 The purpose of this study was to identify somatic (tumor-specific) mutations in endometrial carcinosarcoma tumor exomes. The dataset was generated at the NIH Intramural Sequencing Center (NISC) and NHGRI by next generation sequencing the exomes of 14 de-identified primary tumor DNAs and matched non-tumor DNAs.
Länk
Nyckelord
Versioner (1)
- 2023-06-14 2023-06-14 - Chiara Middel
Rättsinnehavare
Daphne W. Bell, PhD, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA
Uppladdad den
14 juni 2023
DOI
För en begäran logga in.
Licens
Creative Commons BY 4.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
dbGaP phs001152 Somatic Mutational Analysis by Exome Sequencing Endometrial Carcinosarcomas
Subject ID, sample ID, and sample use variable obtained from participants with endometrial carcinosarcomas and involved in the "Somatic Mutational Analysis by Exome Sequencing Endometrial Carcinosarcomas" project.
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID, consent group, and affection status of participants with endometrial carcinosarcomas tumors and involved in the "Somatic Mutational Analysis by Exome Sequencing Endometrial Carcinosarcomas" project.
- Subject ID, sample ID, and sample use variable obtained from participants with endometrial carcinosarcomas and involved in the "Somatic Mutational Analysis by Exome Sequencing Endometrial Carcinosarcomas" project.
- Subject ID and sex of participants with endometrial carcinosarcomas and involved in the "Somatic Mutational Analysis by Exome Sequencing Endometrial Carcinosarcomas" project.
- Sample ID, body site where sample was collected, analyte type, tumor status of sample, histological type of sample, primary tumor or metastasis, primary tumor location, and name of the center which conducted sequencing of samples obtained from participants with endometrial carcinosarcomas and involved in the "Somatic Mutational Analysis by Exome Sequencing Endometrial Carcinosarcomas" project.
Similar models
Subject ID, sample ID, and sample use variable obtained from participants with endometrial carcinosarcomas and involved in the "Somatic Mutational Analysis by Exome Sequencing Endometrial Carcinosarcomas" project.
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID, consent group, and affection status of participants with endometrial carcinosarcomas tumors and involved in the "Somatic Mutational Analysis by Exome Sequencing Endometrial Carcinosarcomas" project.
- Subject ID, sample ID, and sample use variable obtained from participants with endometrial carcinosarcomas and involved in the "Somatic Mutational Analysis by Exome Sequencing Endometrial Carcinosarcomas" project.
- Subject ID and sex of participants with endometrial carcinosarcomas and involved in the "Somatic Mutational Analysis by Exome Sequencing Endometrial Carcinosarcomas" project.
- Sample ID, body site where sample was collected, analyte type, tumor status of sample, histological type of sample, primary tumor or metastasis, primary tumor location, and name of the center which conducted sequencing of samples obtained from participants with endometrial carcinosarcomas and involved in the "Somatic Mutational Analysis by Exome Sequencing Endometrial Carcinosarcomas" project.